Publications by authors named "R W Frenck"
Article Synopsis
- The CDC and ACIP endorse COVID-19 vaccination for patients with inborn errors of immunity (IEI), but there's limited knowledge on its safety and impact on infection severity in these patients.
- A study involving a registry of 1,245 IEI patients across 24 countries was conducted to gather data on vaccination frequency, safety, and effectiveness, revealing that 64.7% were vaccinated, primarily with mRNA vaccines.
- Results showed that vaccinated patients had significantly lower hospitalization and ICU admission rates when infected with COVID-19, indicating that vaccination is both safe and effective in reducing the severity of the disease in IEI patients.
Shigella spp. are a leading bacterial cause of diarrhea. No widely licensed vaccines are available and there is no generally accepted correlate of protection.
View Article and Find Full Text PDFPurpose: Identify variables, including moderating variables, associated with adolescents, young adults, and parents' intention to receive a COVID-19 vaccine in January 2021.
Design: Cross-sectional survey.
Setting: United States Midwestern academic medical center.
B memory (BM) cell responses were evaluated using peripheral blood mononuclear cells that were collected and cryopreserved during a Phase 1 trial of two live Shigella sonnei vaccine candidates WRSs2 and WRSs3. An ELISpot assay was used to measure IgG+ and IgA+ BM cell responses against S. sonnei LPS, IVP and IpaB antigens.
View Article and Find Full Text PDFArticle Synopsis
- - The COVID-19 pandemic has significantly impacted global health, notably affecting both adults and children, with a focus on the increasing attention towards children's health during this crisis.
- - As of September 2023, three COVID-19 vaccines are authorized in the U.S., with genomic surveillance showing the XBB sublineages of SARS-CoV-2 as the most prevalent variants, making up over 99% of sequenced samples.
- - Updated vaccination guidelines now recommend the 2023-2024 Omicron-XBB.1.5-adapted monovalent COVID-19 vaccine to boost protection against these circulating variants, confirming the vaccines' safety and effectiveness for children and adolescents.